Leerink Partners Raises Price Targets for Axogen and Replimune
Leerink Partners lifted its Axogen price target to $56 from $52 and Replimune's to $31 from $19, per Dow Jones Newswires citing Benzinga.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Leerink Partners raised its price target on Axogen (AXGN) to $56 from $52 and kept its Outperform rating, according to Dow Jones Newswires, which cited Benzinga. The item was published at 19:02 GMT.
At 19:11 GMT, the same firm lifted its target on Replimune Group to $31 from $19.
why it matters
Target changes from a single brokerage are routine and reflect one analyst's view of a stock's value, not a company decision or new financial results. Their market impact is usually limited, though they can shape sentiment around the names involved.
tags
instruments
sources
- Axogen Price Target Raised to $56.00/Share From $52.00 by Leerink Partners — Dow Jones Newswires, 29 October 2026 at 19:02 UTC
- Replimune Group Price Target Raised to $31.00/Share From $19.00 by Leerink Partners — Dow Jones Newswires, 29 October 2026 at 19:11 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗